Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant
- PMID: 32088909
- DOI: 10.1007/s12020-020-02209-4
Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant
Abstract
Purpose: Recent guidelines on adrenal incidentalomas suggested in patients with an indeterminate adrenal mass and no significant hormone excess that follow up with a repeat noncontrast CT or MRI after 6-12 months may be an option.
Methods: We report the case of a 32-year-old woman who presented with a 2.9 × 1.9 cm left adrenal incidentaloma that was stable in size for 4 years. Ten years later the left adrenal mass was a stage IV adrenocortical carcinoma (ACC).
Results: In 2006, a 32-year-old French Canadian woman was referred to endocrinology for a left 2.9 × 1.9 cm incidentally discovered adrenal mass (31 HU). She had normal hormonal investigation. The patient was followed with adrenal imaging and hormonal investigation yearly for 4 years and the lesion stayed stable in size over the 4 years. Ten years later, in 2016, the patient presented with renal colic. Urological CT unexpectedly revealed that the left adrenal mass was now measuring 9 × 8.2 cm and 2 new hepatic lesions were found. Biochemical workup demonstrated hypercorticism and hyperandrogenemia: plasma cortisol after 1 mg overnight DST of 476 nmol/L and DHEA-S of 14.0 μmol/L (N 0.9-6.5). Twenty-four hour urine steroid profiling was consistent with an adrenocortical carcinoma (ACC) co-secreting cortisol, androgens and glucocorticoid precursors. The diagnosis of ACC with hepatic ACC metastases was confirmed at histology. Following genetic analysis, germline heterozygous variant of uncertain significance (VUS) was identified in the exon 16 of the APC gene (c.2414G > A, p.Arg805Gln). Immunohistochemical staining's of the ACC was positive for IGF-2 and cytoplasmic/nuclear β-catenin staining.
Conclusions: This case illustrates that (1) small adrenal incidentaloma stable in size may evolve to ACC and (2) better genetic characterization of these patients may eventually give clues on this unusual evolution.
Keywords: APC gene; Adrenal incidentaloma; Adrenocortical carcinoma.
Similar articles
-
A case of adrenocortical carcinoma diagnosed 9 years after the discovery of adrenal incidentaloma.Endocr J. 2022 Dec 28;69(12):1415-1421. doi: 10.1507/endocrj.EJ22-0171. Epub 2022 Aug 6. Endocr J. 2022. PMID: 35934796
-
From benign adrenal incidentaloma to adrenocortical carcinoma: an exceptional random event.Eur J Endocrinol. 2017 Jun;176(6):K15-K19. doi: 10.1530/EJE-17-0037. Epub 2017 Mar 27. Eur J Endocrinol. 2017. PMID: 28348073
-
An Interesting Case of Hepatic Adrenocortical Carcinoma.Acta Med Indones. 2018 Jul;50(3):257-259. Acta Med Indones. 2018. PMID: 30333277
-
Surgical treatment of adrenal carcinoma.J Visc Surg. 2017 Oct;154(5):335-343. doi: 10.1016/j.jviscsurg.2017.06.010. Epub 2017 Jul 25. J Visc Surg. 2017. PMID: 28754418 Review.
-
Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management.Abdom Radiol (NY). 2020 Apr;45(4):945-963. doi: 10.1007/s00261-019-02371-y. Abdom Radiol (NY). 2020. PMID: 31894378 Review.
Cited by
-
Diagnostic dilemmas: a multi-institutional retrospective analysis of adrenal incidentaloma pathology based on radiographic size.BMC Urol. 2022 Apr 30;22(1):73. doi: 10.1186/s12894-022-01024-5. BMC Urol. 2022. PMID: 35501776 Free PMC article.
-
Adrenocortical stem cells in health and disease.Nat Rev Endocrinol. 2025 Aug;21(8):464-481. doi: 10.1038/s41574-025-01091-2. Epub 2025 Mar 10. Nat Rev Endocrinol. 2025. PMID: 40065108 Review.
-
Transformation of a Benign Adrenocortical Adenoma to a Metastatic Adrenocortical Carcinoma Is Rare But It Happens.JCEM Case Rep. 2024 Jul 30;2(8):luae131. doi: 10.1210/jcemcr/luae131. eCollection 2024 Aug. JCEM Case Rep. 2024. PMID: 39081696 Free PMC article.
-
Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021.Curr Opin Oncol. 2022 Jan 1;34(1):19-28. doi: 10.1097/CCO.0000000000000799. Curr Opin Oncol. 2022. PMID: 34669649 Free PMC article. Review.
References
-
- M. Fassnacht, W. Arlt, I. Bancos, H. Dralle, J. Newell-Price, A. Sahdev, A. Tabarin, M. Terzolo, S. Tsagarakis, O.M. Dekkers, Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 175(2), G1–G34 (2016). https://doi.org/10.1530/EJE-16-0467 - DOI - PubMed - PMC
-
- J.M. Hines, I. Bancos, C. Bancos, R.D. Singh, A.V. Avula, W.F. Young, S.K. Grebe, R.J. Singh, High-resolution, accurate-mass (HRAM) mass spectrometry urine steroid profiling in the diagnosis of adrenal disorders. Clin. Chem. 63(12), 1824–1835 (2017). https://doi.org/10.1373/clinchem.2017.271106 - DOI - PubMed
-
- J.M. Schwarz, D.N. Cooper, M. Schuelke, D. Seelow, MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11(4), 361–362 (2014). https://doi.org/10.1038/nmeth.2890 - DOI - PubMed
-
- D. Salgado, J.P. Desvignes, G. Rai, A. Blanchard, M. Miltgen, A. Pinard, N. Levy, G. Collod-Beroud, C. Beroud, UMD-predictor: a high-throughput sequencing compliant system for pathogenicity prediction of any human cDNA substitution. Hum. Mutat. 37(5), 439–446 (2016). https://doi.org/10.1002/humu.22965 - DOI - PubMed - PMC
-
- J. Bendl, J. Stourac, O. Salanda, A. Pavelka, E.D. Wieben, J. Zendulka, J. Brezovsky, J. Damborsky, PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. PLoS Comput. Biol. 10(1), e1003440 (2014). https://doi.org/10.1371/journal.pcbi.1003440 - DOI - PubMed - PMC
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous